Tarsus Pharmaceuticals, Inc. TARS Development and Regulatory Milestone — Maximum milestone payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:CollaborativeArrangementMaximumMilestonePayment.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s development and regulatory milestone — maximum milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s development and regulatory milestone — maximum milestone payments?
- Tarsus Pharmaceuticals, Inc. (TARS) reported development and regulatory milestone — maximum milestone payments of $20M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s development and regulatory milestone — maximum milestone payments changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s development and regulatory milestone — maximum milestone payments decreased by 0.0% year-over-year, from $20M to $20M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s development and regulatory milestone — maximum milestone payments?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s development and regulatory milestone — maximum milestone payments has grown at a -7.0% compound annual growth rate (CAGR), from $92.5M to $80M.
- What does development and regulatory milestone — maximum milestone payments mean?
- This metric represents the aggregate ceiling of potential milestone payments that could be earned under existing licensing or collaboration agreements for a specific product or segment. It defines the total upside potential of the contractual arrangement should all clinical and regulatory hurdles be cleared. It is a key indicator of the maximum contractual value of a partnership agreement.